XUANZHUBIO-B(02575): The innovative drug Xuan Yuening has been included in the 2025 National Basic Medical Insurance Catalog for the first time.

XUANZHUBIO-B(02575) announced that the innovative drug Pyoloxyline tablets (brand name: Xuan Yue Ning) independently developed by the company has been included for the first time in the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List (2025)" (2025 National Basic Medical Insurance List). The 2025 National Basic Medical Insurance List will be officially implemented on January 1, 2026. This medical insurance negotiation result will help the company further improve the affordability and accessibility of Xuan Yue Ning among patients, promote the further market expansion of the drug, increase sales scale, and have a positive impact on the long-term operation and development of the company. The company will actively cooperate to promote the implementation of medical insurance policies, continue to promote hospital access, expand core markets, and increase market coverage, in order to continuously improve the accessibility of medication for patients.